InsidersTradesSigma
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Explore the detailed record of transactions filed by Vivaldi Coelho Rogerio, Chairman & CEO. Director active across 3 companies, notably Sigilon Therapeutics, Inc.. In total, 12 disclosures have been logged. Split: 1 buy · 2 sells. Total volume traded: €347k. History available since 4 November 2021. The latest transaction was disclosed on 2 July 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations
Vivaldi Coelho Rogerio is Président-Directeur Général. He has 12 filings in total. Among the sampled recent filings, the period runs from 2021-11-05 to 2026-07-07, with EUR 102293 of buys and EUR 244989 of sells, and the most frequent transaction nature is Attribution.